Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries
M K
MK
Wolbink
G J
GJ
Stapel
S O
SO
de Groot
E R
ER
Dijkmans
B A C
BA
Aarden
L A
LA
van der Horst-Bruinsma
I E
IE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D000917:Antibody Formation; D018501:Antirheumatic Agents / Q000097:blood / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab